GI
SAGE

GAMMA Investing’s Sage Therapeutics SAGE Stock Holding History

GAMMA Investing’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-189
Closed -$1.72K – 3916
2025
Q2 		$1.72K Sell
189
-831
-81% -$6.11K ﹤0.01% 3435
2025
Q1 		$8.11K Buy
1,020
+970
+1,940% +$7.1K ﹤0.01% 2853
2024
Q4 		$272 Sell
50
-26
-34% -$159 ﹤0.01% 3671
2024
Q3 		$549 Sell
76
-58
-43% -$531 ﹤0.01% 3375
2024
Q2 		$1.46K Buy
134
+18
+16% +$231 ﹤0.01% 2971
2024
Q1 		$2.17K Buy
116
+52
+81% +$1.2K ﹤0.01% 2724
2023
Q4 		$1.64K Buy
+64
New +$1.27K ﹤0.01% 2643

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

GAMMA Investing's SAGE Position: Q3 2025 in Review

GAMMA Investing sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 189 shares — an estimated $1.72K sold.

GAMMA Investing first reported a position in SAGE in Q4 2023 and held it in 7 quarters. The position peaked at $8.11K in Q1 2025. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • GAMMA Investing reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • GAMMA Investing sold 189 Sage Therapeutics shares in Q3 2025, an estimated $1.72K.
  • GAMMA Investing first reported a position in Sage Therapeutics in Q4 2023 and held it in 7 quarters.
  • GAMMA Investing's Sage Therapeutics position peaked at $8.11K in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on GAMMA Investing's 13F filing for Q3 2025, filed 2 Oct 2025.